3,4-二氢-1(2H)-喹啉羧酸乙酯 | 54915-68-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 中文名称: 3,4-二氢-1(2H)-喹啉羧酸乙酯
• 英文名称: 1-(ethoxycarbonyl)-1,2,3,4-tetrahydroquinoline
• 英文别名: Ethyl 3,4-dihydroquinoline-1(2h)-carboxylate；ethyl 3,4-dihydro-2H-quinoline-1-carboxylate
• CAS: 54915-68-3
• 化学式: C₁₂H₁₅NO₂
• mdl: MFCD01685692
• 分子量: 205.257
• InChiKey: YQBRPZBLROENTD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.416
• 拓扑面积：
  29.5
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2933499090

反应信息

• 作为反应物：
  描述：

  3,4-二氢-1(2H)-喹啉羧酸乙酯 在 sodium 作用下， 以 正庚烷 为溶剂， 反应 2.5h， 以27%的产率得到oxalyl bis(tetrahydroquinolinide)
  参考文献：
  名称：

  Sodium metal-promoted condensations of carbamates

  摘要：

  DOI：

  10.1021/jo00392a042
• 作为产物：
  描述：

  ethyl (3-bromopropyl)(2-iodophenyl)carbamate 在 吡啶 、 2-丁烯酸乙酯 、 nickel dichloride 、 锌 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 2.5h， 以53%的产率得到3,4-二氢-1(2H)-喹啉羧酸乙酯
  参考文献：
  名称：

  镍在室温下介导未活化的烷基溴化物和芳基碘化物的分子间和分子内还原交叉偶联

  摘要：

  已开发出室温下未活化的烷基溴和芳基碘的镍介导的分子间还原性交叉偶联反应，并成功地扩展到较少探索的分子内版本和串联环化-分子间交叉偶联。线性稠合的全氢呋喃[2,3- b ]呋喃（吡喃）和螺环骨架的高度立体选择性（或立体定向）合成可以快速获得这些有用的结构单元，这在相关天然产物的合成中可能具有潜在的价值。给出了形成连续立体中心的合理解释。

  DOI：

  10.1002/chem.201200190

文献信息

• [EN] 1,2,4-SUBSTITUERTE 1,2,3,4-TETRAHYDRO-AND 1,2 DIHYDRO-QUINOLINE AND 1,2,3,4-TETRAHYDRO-QUINOXALINE DERIVATIVES AS CETP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROSIS AND OBESITY<br/>[FR] DERIVES DE 1,2,3,4-TETRAHYDRO- ET 1,2 DIHYDRO-QUINOLEINE ET 1,2,3,4-TETRAHYDRO-QUINOXALINE 1,2,4-SUBSTITUES, UTILES COMME INHIBITEURS DE CETP POUR LE TRAITEMENT DE L'ATHEROSCLEROSE ET DE L'OBESITE
  申请人：PFIZER PROD INC

  公开号：WO2004085401A1

  公开（公告）日：2004-10-07

  Quinoline and quinoxaline compounds of formula I and III wherein the subtituent are as defined in claims 1 and 15, pharmaceutical compositions containing such compounds and the use of such compounds to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and/or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases in some mammals, including humans.

  喹啉和喹啉并喹啉化合物的公式I和III，其中取代基如权利要求1和15中所定义的，含有这种化合物的药物组合物以及使用这种化合物来提高某些血浆脂质水平，包括高密度脂蛋白胆固醇，并降低其他一些血浆脂质水平，如LDL胆固醇和甘油三酯，并因此治疗由HDL胆固醇水平低和/或LDL胆固醇和甘油三酯水平高加重的疾病，如动脉粥样硬化和心血管疾病在某些哺乳动物中，包括人类。
• [EN] SMALL MOLECULE MODIFIERS OF MICRORNA MIR-122<br/>[FR] MODIFICATEURS À PETITE MOLÉCULE DE MICROARN MIR-122
  申请人：UNIV NORTH CAROLINA STATE

  公开号：WO2011091209A1

  公开（公告）日：2011-07-28

  MicroRNAs are a class of endogenous regulators of gene function. Aberrant regulation of microRNAs has been linked to various human diseases, most importantly cancer. Small molecule intervention of microRNA misregulation has the potential to provide new therapeutic approaches to such diseases. microRNA miR-122 is the most abundant microRNA in the liver and is involved in hepatocellular carcinoma development and hepatitis C virus (HCV) infection. Small molecule inhibitors and activators of the microRNA miR-122 are described, and methods for their identification are reported. These small molecule inhibitors reduce viral replication in liver cells and thus represent a new approach to the treatment of HCV infections. Moreover, small molecule activation of miR-122 in liver cancer cells selectively induced apoptosis through caspase activation, and thus has implications in cancer chemotherapy.

  微小RNA是一类内源性基因功能调节因子。微小RNA的异常调节与各种人类疾病有关，尤其是癌症。对微小RNA的小分子干预可能为这些疾病提供新的治疗途径。微小RNA miR-122是肝脏中最丰富的微小RNA，参与了肝细胞癌和丙型肝炎病毒（HCV）感染的发展。描述了微小RNA miR-122的小分子抑制剂和激活剂，并报告了其鉴定方法。这些小分子抑制剂可以减少肝细胞中的病毒复制，因此代表了治疗HCV感染的新方法。此外，在肝癌细胞中通过小分子激活miR-122可选择性诱导凋亡，通过激活半胱氨酸蛋白酶而在癌症化疗中具有重要意义。
• Melanin-concentrating hormone antagonist
  申请人：——

  公开号：US20030158177A1

  公开（公告）日：2003-08-21

  A melanin-concentrating hormone antagonist comprising a compound of the formula: 1 wherein R is hydrogen atom or a cyclic group which may be substituted; X is a bond or a spacer having a main chain of 1 to 10 atoms; Y is a spacer having a main chain of 1 to 6 atoms; ring A is benzene ring which may be further substituted; ring B is a 5- to 9-membered nitrogen-containing non-aromatic heterocyclic ring which may be further substituted; R 1 and R 2 are the same or different and are hydrogen atom, a hydrocarbon group which may be substituted or a heterocyclic group which may be substituted; or R 1 and R 2 , together with the adjacent nitrogen atom, may form a nitrogen-containing heterocyclic ring which may be substituted; or R 2 , together with the adjacent nitrogen atom and Y, may form a nitrogen-containing heterocyclic ring which may be substituted; or a salt thereof is useful as a preventive or therapeutic agent for obesity, etc.

  一种黑素浓缩激素拮抗剂，包括以下结构的化合物：其中R是氢原子或可能被取代的环状基团；X是具有1到10个原子主链的键或间隔物；Y是具有1到6个原子主链的间隔物；环A是苯环，可能进一步被取代；环B是一个含氮的非芳香杂环环，成员数为5到9，可能进一步被取代；R1和R2相同或不同，是氢原子、可能被取代的烃基或可能被取代的杂环基；或者R1和R2，与相邻的氮原子一起，可以形成一个可能被取代的含氮杂环环；或者R2，与相邻的氮原子和Y一起，可以形成一个可能被取代的含氮杂环环；或其盐可用作肥胖等疾病的预防或治疗剂。
• [EN] 4-CARBOXYAMINO-2-SUBSTITUTED-1,2,3,4-TETRAHYDROQUINOLINES AS CETP INHIBITORS<br/>[FR] 4-CARBOXYAMINO-2-SUBSTITUE-1,2,3,4-TETRAHYDROQUINOLINES UTILISEES COMME INHIBITEURS DE CETP
  申请人：PFIZER PROD INC

  公开号：WO2000017164A1

  公开（公告）日：2000-03-30

  Cholesteryl ester transfer protein inhibitors of the Formula (I), a prodrug thereof, or a pharmaceutically acceptable salt of said compound or of said prodrug, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and/or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases in some mammals, including humans.

  公式（I）的胆固醇酯转移蛋白抑制剂，其前药，或该化合物或该前药的药学上可接受的盐，包含这种抑制剂的制药组合物以及使用这种抑制剂来提高某些血浆脂质水平，包括高密度脂蛋白胆固醇，并降低某些其他血浆脂质水平，如低密度脂蛋白胆固醇和甘油三酯，从而治疗低密度脂蛋白胆固醇和/或高甘油三酯水平加重的疾病，如动脉粥样硬化和某些哺乳动物，包括人类的心血管疾病。
• SMALL MOLECULE MODIFIERS OF MICRORNA MIR-122
  申请人：Deiters Alexander

  公开号：US20130005759A1

  公开（公告）日：2013-01-03

  MicroRNAs are a class of endogenous regulators of gene function. Aberrant regulation of microRNAs has been linked to various human diseases, most importantly cancer. Small molecule intervention of microRNA misregulation has the potential to provide new therapeutic approaches to such diseases. microRNA miR-122 is the most abundant microRNA in the liver and is involved in hepatocellular carcinoma development and hepatitis C virus (HCV) infection. Small molecule inhibitors and activators of the microRNA miR-122 are described, and methods for their identification are reported. These small molecule inhibitors reduce viral replication in liver cells and thus represent a new approach to the treatment of HCV infections. Moreover, small molecule activation of miR-122 in liver cancer cells selectively induced apoptosis through caspase activation, and thus has implications in cancer chemotherapy.

  MicroRNAs是一类内源性基因调控因子。微小RNA的异常调控已与各种人类疾病，尤其是癌症相关联。小分子干预微小RNA的错调可能为这些疾病提供新的治疗方法。微小RNA miR-122是肝脏中最丰富的微小RNA，参与肝细胞癌的发展和丙型肝炎病毒（HCV）感染。描述了微小RNA miR-122的小分子抑制剂和激活剂，并报道了其鉴定方法。这些小分子抑制剂能够减少肝细胞中的病毒复制，因此代表了治疗HCV感染的新方法。此外，小分子激活miR-122在肝癌细胞中选择性地通过caspase激活诱导凋亡，因此在癌症化疗中具有重要意义。